08:02 AM EST, 01/15/2025 (MT Newswires) -- Keros Therapeutics ( KROS ) said Wednesday it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."

The decision includes all treatment arms, including the 1.5 mg/kg and placebo groups.

Keros Therapeutics ( KROS ) halted higher dose treatments of 3.0 mg/kg and 4.5 mg/kg last December due to similar concerns.

Keros Therapeutics ( KROS ) shares were down more than 16% in recent premarket activity.

Price: 10.39, Change: -2.09, Percent Change: -16.75